Magrolimab plus docetaxel improved outcomes in sufferers with metastatic NSCLC and excessive CD47 expression, based on a examine.
Improved outcomes had been seen with magrolimab plus docetaxel in sufferers with metastatic non-small cell lung most cancers (NSCLC) who had larger CD47 expressions, based on a presentation on the section 2 ELEVATELung&UC trial on the 2024 Society for Immunotherapy of Most cancers (SITC) Annual Assembly.
Magrolimab is a kind of monoclonal antibody that targets CD47 by binding to it, based on the Nationwide Most cancers Institute. When the drug binds to CD47, it helps destroy the most cancers cells instantly. Within the examine, magrolimab was mixed with docetaxel, a kind of chemotherapy.
The examine included 31 sufferers with metastatic NSCLC who beforehand obtained remedy within the second- or later-line setting. Researchers discovered that sufferers with NSCLC with confirmed partial responses (PRs) or full responses (CRs) to magrolimab plus docetaxel had larger baseline ranges of CD47 expression.
Amongst sufferers with CD47 expression on greater than 50% of tumor cells, the median progression-free survival (PFS) was 8.9 months versus 2.6 months for these with baseline CD47 expression under 50%. The median PFS within the NSCLC inhabitants handled with magrolimab plus docetaxel was 5.4 months.
Glossary:
Increased CD47 expression: a marker in some cancers, equivalent to NSCLC, that helps decide survival outcomes. Increased CD47 expression is related to poorer survival outcomes.
Partial responses (PRs): shrinkage in sufferers’ tumors after remedy.
Full responses (CRs): disappearance of tumors after remedy.
Development-free survival (PFS): time sufferers reside with out their most cancers worsening or spreading.
ECOG efficiency rating: measures sufferers’ independence when performing day by day duties. A rating of 0 means full independence and 4 means full dependence on others.
Total responses: proportion of sufferers within the examine who had a partial or full response to remedy.
Steady illness (SD): the illness has not gotten worse or higher with remedy.
Progressive illness (PD): illness that has worsened or unfold after remedy.
“Regardless of a restricted pattern dimension, the correlation between CD47 expression and higher end result in each [ELEVATELung&UC] and in Tempus real-world knowledge of sufferers handled with chemotherapy and/or [immunotherapy] suggests a optimistic prognostic function for CD47 in metastatic NSCLC,” lead examine creator Nick van Buuren, of Gilead Sciences and coauthors, wrote in a poster of the information.
Extra Concerning the ELEVATE-Lung&UC Trial
Among the many 31 sufferers with metastatic NSCLC within the examine who obtained remedy (intent-to-treat inhabitants; ITT), the median age was 65 years. Most sufferers had been male (77.4%), White (90.3%), had stage 4 illness (96.8%), had an ECOG efficiency rating of 1 at baseline (54.8%) and had been former people who smoke (58.1%). One of the best total responses to magrolimab plus docetaxel on this inhabitants included CR or PR (19.4%), steady illness (SD; 38.7%) and progressive illness (PD; 16.1%).
The biomarker-evaluable inhabitants was a subset of 24 sufferers with stage 4 NSCLC who had reportable baseline CD47 outcomes. The affected person traits and finest total response charges mirrored these noticed within the ITT inhabitants. On this inhabitants, the median age was 64 years. Most sufferers had been male (75%), White (87.5%), had an ECOG efficiency rating of 1 at baseline (62.5%) and had been former people who smoke (50%). Finest total responses to magrolimab plus docetaxel on this inhabitants included CR or PR (20.8%), SD (37.5%) and PD (12.5%).
The ELEVATE-Lung&UC trial evaluated the protection, tolerability and effectiveness of magrolimab plus docetaxel in sufferers with metastatic NSCLC, metastatic small cell lung most cancers and metastatic bladder most cancers.
Sufferers with mNSCLC will need to have obtained one or two prior traces of platinum-based chemotherapy, a checkpoint inhibitor or each.
Sufferers obtained magrolimab at a priming dose of 1 milligram per kilogram (mg/kg) on cycle at some point one, adopted by a weekly dose of 30 mg/kg from cycle at some point eight to cycle two day 15. After, sufferers obtained a upkeep dose of 60 mg/kg each three weeks from cycle three day one onward. Docetaxel was given at 75 mg per sq. meter each three weeks.
In February 2024, Gilead introduced a worldwide pause in enrollment to research investigating magrolimab in sufferers with strong tumors, together with ELEVATELung&UC, to evaluation the risk-benefit profile of magrolimab throughout the trials. The FDA subsequently requested a partial medical maintain on these trials.
Gilead later determined to terminate the ELEVATELung&UC trial.
Reference:
“Biomarker evaluation of magrolimab plus docetaxel in sufferers from ELEVATE-Lung and UC, a section 2 multicohort examine” by Nick van Buuren, et al., 2024 SITC Annual Assembly.
For extra information on most cancers updates, analysis, and schooling, don’t overlook to subscribe to CURE®’s newsletters right here.
